Phase-3 Randomized Controlled Trials on Exclusion of Participants With Kidney Disease in COVID-19
Kidney Int Rep
.
2021 Jan;6(1):196-199.
doi: 10.1016/j.ekir.2020.10.010.
Epub 2020 Oct 21.
Authors
Api Chewcharat
1
,
Yuan-Ting Chang
2
,
Meghan E Sise
3
,
Roby P Bhattacharyya
4
,
Megan B Murray
5
6
,
Sagar U Nigwekar
3
Affiliations
1
Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, Massachusetts, USA.
2
Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, United Kingdom.
3
Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
4
Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
5
Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
6
Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
PMID:
33106779
PMCID:
PMC7577277
DOI:
10.1016/j.ekir.2020.10.010
No abstract available
Grants and funding
U01 DK123818/DK/NIDDK NIH HHS/United States